Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.68 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | F13A1 | P00488 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA6 | P23280 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | THPO | P40225 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19952912 | 1.00 | GSR (0.68) | GSRGNAI3GNAO1GNAI1MAOA | |
| SCHEMBL19952914 | 1.00 | GSR (0.68) | GSRGNAI3GNAO1GNAI1MAOA | |
| SCHEMBL19952847 | 1.00 | GSR (0.68) | GSRGNAI3GNAO1GNAI1MAOA | |
| Hydrochloric Acid SCHEMBL19952983 | 0.98 | GSR (0.66) | GSRGNAI3GNAO1GNAI1MAOA | |
| Hydrochloric Acid SCHEMBL19952846 | 0.98 | GSR (0.66) | GSRGNAI3GNAO1GNAI1MAOA | |
| Hydrochloric Acid SCHEMBL19952984 | 0.98 | GSR (0.66) | GSRGNAI3GNAO1GNAI1MAOA | |
| Hydrochloric Acid SCHEMBL19952849 | 0.98 | GSR (0.66) | GSRGNAI3GNAO1GNAI1MAOA | |
| Hydrochloric Acid SCHEMBL19953108 | 0.98 | GSR (0.66) | GSRGNAI3GNAO1GNAI1MAOA | |
| Hydrochloric Acid SCHEMBL19952838 | 0.98 | GSR (0.66) | GSRGNAI3GNAO1GNAI1MAOA | |
| SCHEMBL22976016 | 0.96 | GSR (0.74) | GSRGNAI3GNAO1GNAI1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465582-B2 | (S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis | Temple University—Of the Commonwealth System of Higher Education (US) | 2025-11-11 | — | — | US | claimed |
| EP-4595969-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | Temple University Of The Commonwealth System Of Higher Education (US) | 2025-08-06 | — | — | EP | claimed |
| EP-3509575-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | UNIV TEMPLE (US) | 2025-03-19 | — | — | EP | claimed |
| US-20230172886-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-06-08 | — | — | US | claimed |
| CN-110139644-B | Compositions and methods for treating insulin resistance | 坦普尔大学 | 2023-05-23 | — | — | CN | claimed |
| US-11596615-B2 | Compositions and methods for treatment of insulin resistance | Temple University—Of the Commonwealth System of Higher Education (US) | 2023-03-07 | — | — | US | claimed |
| EP-4138812-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | Temple University - Of The Commonwealth System of Higher Education (US) | 2023-03-01 | — | — | EP | claimed |
| CN-115461049-A | (S) -2-amino-6- ((3-aminopropyl) amino) hexanoic Acid (APL) for the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis | 坦普尔大学 | 2022-12-09 | — | — | CN | claimed |
| WO-2021217006-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-10-28 | — | — | WO | claimed |
| US-20210046030-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2021-02-18 | — | — | US | claimed |
| US-10729670-B2 | Compositions and methods for treatment of insulin resistance | Temple University—Of The Commonwealth Systems Of Higher Education (US) | 2020-08-04 | — | — | US | claimed |
| US-20190192462-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2019-06-27 | — | — | US | claimed |
| US-12465582-B2 | (S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis | Temple University—Of the Commonwealth System of Higher Education (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4595969-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | Temple University Of The Commonwealth System Of Higher Education (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-3509575-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | UNIV TEMPLE (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20230172886-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2023-06-08 | — | — | US | disclosed |
| US-20190192462-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2019-06-27 | — | — | US | disclosed |
| US-20190192462-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2019-06-27 | — | — | US | disclosed |
| WO-2018049019-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2018049019-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11596615-B2 | Compositions and methods for treatment of insulin resistance | GPR119, INSR, IAPP | GSR 185/4885GNAI3 2623/4885GNAO1 3016/4885 |
| US-10729670-B2 | Compositions and methods for treatment of insulin resistance | GPR119, INSR, IAPP | GSR 185/4885GNAI3 2623/4885GNAO1 3016/4885 |
| US-20190192462-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | GPR119, INSR, IAPP | GSR 185/4885GNAI3 2623/4885GNAO1 3016/4885 |
| US-20210046030-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN RESISTANCE | GPR119, INSR, IAPP | GSR 185/4885GNAI3 2623/4885GNAO1 3016/4885 |
| US-20230172886-A1 | (S)-2-AMINO-6-((3-AMINOPROPYL)AMINO)HEXANOIC ACID (APL) FOR USE IN THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH), LIVER INFLAMMATION, HEPATOCELLULAR BALLOONING, LIVER FIBROSIS AND STEATOSIS | FABP1, AADAT, FABP6 | GSR 2640/4885GNAI3 4000/4885GNAO1 3617/4885 |
| US-12465582-B2 | (S)-2-amino-6-((3-aminopropyl)amino)hexanoic acid (APL) for use in the treatment of non-alcoholic steatohepatitis (NASH), liver inflammation, hepatocellular ballooning, liver fibrosis and steatosis | FABP1, AADAT, FABP6 | GSR 2640/4885GNAI3 4000/4885GNAO1 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.